Mice Lacking Adiponectin Show Decreased Hepatic Insulin Sensitivity and Reduced Responsiveness to Peroxisome Proliferator-activated Receptor γ Agonists

Abstract

The adipose tissue-derived hormone adiponectin improves insulin sensitivity and its circulating levels are decreased in obesityinduced insulin resistance. Here, we report the generation of a mouse line with a genomic disruption of the adiponectin locus. We aimed to identify whether these mice develop insulin resistance and which are the primary target tissues affected in this model. Using euglycemic/insulin clamp studies, we demonstrate that these mice display severe hepatic but not peripheral insulin resistance. Furthermore, we wanted to test whether the lack of adiponectin magnifies the impairments of glucose homeostasis in the context of a dietary challenge. When exposed to high fat diet, adiponectin null mice rapidly develop glucose intolerance. Specific PPAR␥ agonists such as thiazolidinediones (TZDs) improve insulin sensitivity by mechanisms largely unknown. Circulating adiponectin levels are significantly up-regulated in vivo upon activation of PPAR␥. Both TZDs and adiponectin have been shown to activate AMP-activated protein kinase (AMPK) in the same target tissues. We wanted to address whether the ability of TZDs to improve glucose tolerance is dependent on adiponectin and whether this improvement involved AMPK activation. We demonstrate that the ability of PPAR␥ agonists to improve glucose tolerance in ob/ob mice lacking adiponectin is diminished. Adiponectin is required for the activation of AMPK upon TZD administration in both liver and muscle. In summary, adiponectin is an important contributor to PPAR␥-mediated improvements in glucose tolerance through mechanisms that involve the activation of the AMPK pathway.Adiponectin/ACRP30 (adipocyte complement-related protein of 30 kDa), an adipocyte-specific secretory protein, has been shown to modulate insulin sensitivity; however, the mechanism(s) by which it acts are not fully understood (1). A number of clinical studies revealed a strong link between whole body insulin sensitivity and circulating adiponectin levels (2). Furthermore, circulating adiponectin is negatively correlated with the body mass index (3). Weight reduction leads to a significant increase in adiponectin plasma levels slightly preceding improvements in insulin sensitivity, thus suggesting a causative role of adiponectin in enhancing insulin sensitivity (4). Adiponectin null mouse models were described previously, however, with somewhat varying outcomes regarding their metabolic phenotype. Kubota et al. (5) noted mild insulin resistance under basal conditions in heterozygotes (60% reduction in adiponectin serum levels) and more severe insulin resistance in adiponectin null animals. This report differed from adiponectin null mice described by Maeda et al. (6) that showed nearly normal insulin sensitivity when fed on a standard laboratory diet but developed severe insulin resistance in as few as 2 weeks on a high fat/high sucrose diet. However, a third independent report of adiponectin null mice by Ma et al. (7) described an unexpected increase in fatty acid oxidation in skeletal muscle...

Metabolic action of peroxisome proliferator-activated receptor γ agonism in rats with exogenous hypercorticosteronemia

“…PPARg agonists are thought to counteract liver lipid deposition mainly indirectly through increasing the secretion of the adipokine adiponectin, which strongly favors hepatic fatty acid oxidation. 55,56 The present findings demonstrate that in normal rats such as the vehicle-implanted rats of the present study, any reduction in liver exposure to CORT that may conceivably occur in response to PPARg agonism is not the cause of the antisteatotic effect of the latter. Notably, HiCORT modestly promoted tissue TG accumulation also in skeletal muscle, an effect that RSG was unable to counteract.…”

Adiponectin Regulation of Stellate Cell Activation via PPARγ-Dependent and -Independent Mechanisms

“…Consistent with these data is the finding that PPAR␥ ligands are less effective in improving the metabolic syndrome in adiponectin-null mice. 18 Given the similarities between PPAR␥ and adiponectin effects, we think that adiponectin may have acted in a PPAR␥-dependent manner. We have clearly shown that adiponectin is a major effector for PPAR␥ actions, but the reverse is not true.…”

“…18,19 Male mice between the ages of 12 and 16 weeks were used for this study. All animals were maintained under temperature-controlled conditions (22 Ϯ 2°C) in 12-hour light/dark cycles with unlimited access to food and water.…”

The ‘beneficial’ adipokines in reproduction and fertility

“…76 In the context of interaction with insulin, small interfering RNA (siRNA) knockdown of APPL1 expression interferes with insulin induction of Akt/PKB in muscle cells. 28 Although direct confirmation is lacking, it may be that APPL1 interacts directly with the insulin receptor.…”